LMAT Financials Lemaitre Vascular Inc

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 28 h ago Overview →

Growth & profitability

Revenue has grown 14.0% per year over the past 5 years.
Net income has grown faster than revenue (22.1% vs 14.0% per year).
Operating margin has expanded, at 27.2% in the latest year.
Free cash flow has grown 18.5% per year over the past 5 years.

Financial health

Operating income covered interest expense 13× in the latest year, down from 22× 5 years ago.

Shareholder returns

Dividends have been paid for 15 consecutive years, consuming 31.4% of earnings and 24.3% of free cash flow.
The dividend has grown 18.7% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
2025	$250M	$58M	71.5%	27.2%	$74M	—	$28M
2024	$220M	$44M	68.6%	23.8%	$37M	—	$26M
2023	$193M	$30M	65.7%	19.0%	$29M	—	$24M
2022	$162M	$21M	64.9%	16.6%	$22M	—	$19M
2021	$154M	$27M	65.7%	23.6%	$30M	—	$14M
2020	$129M	$21M	65.4%	22.3%	$32M	—	$27M
2019	$117M	$18M	68.1%	18.1%	$10M	—	$12M
2018	$106M	$23M	70.0%	26.7%	$16M	—	$26M
2017	$101M	$17M	70.1%	20.9%	$16M	—	$19M
2016	—	$11M	—	—	$14M	—	$24M
2015	—	$8M	—	—	—	—	$27M
2014	—	$4M	—	—	—	—	$19M
2013	—	$3M	—	—	—	—	$15M
2012	—	$3M	—	—	—	—	$16M
2011	—	$2M	—	—	—	—	$20M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
Mar '26	$67M	$16M	72.7%	26.7%	$12M	—	$27M
Dec '25	$64M	$16M	71.7%	29.2%	$21M	—	$28M
Sep '25	$61M	$17M	75.3%	33.3%	$26M	—	$25M
Jun '25	$64M	$14M	70.0%	25.1%	$19M	—	$27M
Mar '25	$60M	$11M	69.2%	21.1%	$8M	—	$25M
Dec '24	$56M	$11M	69.3%	23.1%	$13M	—	$26M
Sep '24	$55M	$11M	67.8%	24.0%	$13M	—	$21M
Jun '24	$56M	$12M	68.9%	25.7%	$8M	—	$22M
Mar '24	$53M	$10M	68.6%	22.2%	$4M	—	$27M
Dec '23	$49M	$8M	68.1%	20.9%	$9M	—	$24M
Sep '23	$47M	$8M	65.0%	19.4%	$11M	—	$18M
Jun '23	$50M	$8M	64.0%	18.9%	$9M	—	$19M
Mar '23	$47M	$6M	65.6%	16.7%	$149000	—	$17M
Dec '22	$41M	$6M	63.6%	17.0%	$3M	—	$19M
Sep '22	$39M	$5M	64.2%	15.8%	$7M	—	$17M
Jun '22	$42M	$4M	66.0%	13.7%	$8M	—	$21M
Mar '22	$40M	$6M	65.6%	20.0%	$4M	—	$16M
Dec '21	$40M	$6M	65.7%	21.0%	$4M	—	$14M
Sep '21	$38M	$7M	64.8%	23.6%	$12M	—	$17M
Jun '21	$41M	$8M	65.8%	27.3%	$8M	—	$22M

Valuation over time

How the market has priced LMAT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 57.1× (Mar '23) to 37.2× (Jun '26).
The price-to-sales ratio has risen from 7.3× (Mar '23) to 8.6× (Jun '26).
The dividend yield has fallen from 0.9% (Mar '23) to 0.8% (Jun '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is LMAT growing its revenue and profit?

Over the past 5 years, Lemaitre Vascular Inc's revenue has grown 14.0% per year, and net income grown 22.1% per year. These are computed facts, not advice.

How much debt does LMAT have?

As of FY2025, Lemaitre Vascular Inc reported — of total debt against $28M of cash; operating income covered interest expense 13×.

What is LMAT's profit margin?

In FY2025, gross margin was 71.5%, operating margin 27.2%, and net margin 23.1%.

What is LMAT's P/E ratio?

As of Jun '26, Lemaitre Vascular Inc traded at a price-to-earnings ratio of about 37.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.